symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
XLO,1.91,0,12218,52600636,0,1.66-4.92,0.19,"Xilio Therapeutics, Inc.",USD,0001840233,US98422T1007,98422T100,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.xiliotx.com,"Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.","Dr. Rene  Russo BCPS, Pharm.D, Pharm.D.",Healthcare,US,84,617 430 4680,828 Winter Street,Waltham,MA,02451,,0,https://financialmodelingprep.com/image-stock/XLO.png,2021-10-22,False,False,True,False,False
